

Nanexa CEO invited as speaker at CRS 2022 Annual Meeting

Nanexa AB today announced that CEO David Westberg has been invited as speaker and the company also got three abstracts approved for publication as posters at CRS 2022 Annual Meeting and Expo, on July 11-15, 2022, in Montreal, Canada.

CRS (Controlled Release Society Annual Meeting) is a large international conference gathering leaders in drug development and business development from most of the larger global pharma companies.

"This year, we will present three posters describing PharmaShell® from different perspectives, and we have also been invited as speakers at the conference. I really look forward to presenting PharmaShell and Nanexa to this audience and hope to establish many new contacts during the conference", said David Westberg, CEO of Nanexa.

For additional information, please contact:

David Westberg – CEO, Nanexa AB (publ)

Phone: +46 70 942 83 03

Email: david.westberg@nanexa.se

www.nanexa.com

Erik Penser Bank is the company's Certified Adviser and can be reached on +46 8 463 83 00, email: certifiedadviser@penser.se

About Nanexa AB (publ)

Nanexa is a pharmaceutical company developing parenteral drug products based on the proprietary and innovative drug delivery system PharmaShell® – the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. Nanexa develops its own products and also has collaboration agreements with several pharma companies, among others AstraZeneca.

Nanexa's share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

Attachments

[Nanexa CEO invited as speaker at CRS 2022 Annual Meeting](#)